Stay updated on Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check2 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.8%
- Check9 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.9%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check30 days agoChange DetectedThe web page has been updated with new results reporting dates and additional details regarding the assessment of tumor response and adverse events. Notably, the section on pregnancy and nursing has been removed, which may impact the understanding of study eligibility for women of child-bearing potential.SummaryDifference6%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.